Cell therapy (NK cells) · Kills target cells · developed by Fate Therapeutics
FT516 is an allogeneic, off-the-shelf natural killer cell product derived from a clonal master induced pluripotent stem cell line and engineered to express a high-affinity, non-cleavable CD16 Fc receptor. It binds the Fc portion of tumor-bound monoclonal antibodies to trigger antibody-dependent cellular cytotoxicity. It is studied in acute myelogenous leukemia and B-cell lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04023071 | Phase 1 | Acute Myelogenous Leukemia | Terminated | FATE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myelogenous LeukemiaB-cell Lymphoma
Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.
See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
FATE catalysts and pipeline →